The Respiratory Syncytial Virus Vaccine and Monoclonal Antibody Landscape: the road to global access

This article provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, the urgent next steps to minimise the vaccine delay are outlined.

Educational Objectives

Educational Aim:

The RSV vaccine and mAb landscape has come a long way since the first vaccine attempts in the 1960s. Researchers can reduce the economic and clinical RSV burden in infants and older adults in HICs and major collaborative efforts need to be urgently undertaken to minimise the RSV vaccine gap to LMICs and this is discussed in the article.

Educational Outcomes:
Upon completion of this module practitioners should have a clear understanding of:

1. Respiratory syncytial virus (RSV) which is a leading cause of lower respiratory tract infections.
2. The RSV vaccine landscape which will continue to further develop in the coming years to protect all people globally.
3. RSV vaccines highlighting different target populations, antigens, and trial results.

Instructions for this Module

• Read the supplied reading material and complete the quiz that follows;
• You have three attempts to pass the quiz;
• The pass grade is 70%;
• You need to pass the quiz to claim your CPD certificate;
• Please click on the CPD certificate link below to claim your CPD certificate and to update your CPD Manager.

If you need any assistance to complete this module, please Contact us